EirGenix

EirGenix Inc., (6589.TT) a Taiwan-based pharmaceutical company, has announced that it has received marketing approval from the European Commission (EC) for its biosimilar version of trastuzumab, known as Roche’s Herceptin. The approval is for the 150mg form of the drug intended for intravenous use, indicated for the treatment of HER2-positive…